<DOC>
	<DOCNO>NCT03065959</DOCNO>
	<brief_summary>The purpose study investigate effect CK-2127107 versus placebo skeletal muscle fatigue assess change baseline versus 14 day treatment sum peak torque isokinetic knee extension . This study also assess effect CK-2127107 physical performance via short physical performance battery ( SPPB ) , stair-climb test 6 minute walk test .</brief_summary>
	<brief_title>A Study Assess Anti-fatigability Effect CK-2127107 Elderly Male Female Subjects With Limitations Mobility</brief_title>
	<detailed_description>Enrolled participant randomize receive either CK-2127107 Placebo first cross receive opposite intervention . The study consist two treatment period 14 day separate washout period 14 day .</detailed_description>
	<mesh_term>Mobility Limitation</mesh_term>
	<criteria>Subject body mass index 18.5 35.0 kg/m2 , inclusive . Subject score great 4 less equal 9 Short physical performance battery ( SPPB ) . Subject able complete 6minute walk test screen without assistive device help another person . Subject able successfully complete prestudy isokinetic knee extension ( 120 contraction ) . These assessment may repeat investigator 's discretion ( within screen window ) . Subject able communicate well investigator understand comply requirement study . Subject minimental state examination ( MMSE ) score great 21 screening . Subject currently follow regular structured exercise weekly activity . A sexually active male subject female partner ( ) childbearing potential eligible : Male subject agree use male condom start screen continue throughout study treatment 28 day final study drug administration . If male subject vasectomy sterile define , male subject 's female partner ( ) utilize 1 form highly effective birth control start screen continue throughout study treatment 90 day male subject receive final study drug administration . Male subject must donate sperm start screen throughout study period , 28 day final study drug administration . Male subject pregnant breastfeeding partner ( ) must agree remain abstinent use condom duration pregnancy time partner breastfeed throughout study period 28 day final study drug administration . Subject agree participate another interventional study participate present study , define signing informed consent form current study completion Followup visit study . Subject previous exposure CK2127107 . Subject liver function test ( aspartate aminotransferase , alanine aminotransferase , alkaline phosphatase , Î³glutamyl transferase total bilirubin ) 1.5 time upper limit normal day 1 . In case , assessment may repeat . Subject estimate glomerular filtration rate le 30 mL/min per 1.73 m2 CockcroftGault equation screen . Subject clinically significant history allergic condition ( include drug allergy , asthma , eczema , anaphylactic reaction , exclude untreated , asymptomatic , seasonal allergy ) prior study drug administration . Subject has/had febrile illness symptomatic viral , bacterial ( include upper respiratory infection ) , fungal ( noncutaneous ) infection within 1 week prior day 1 . Subject condition make subject unsuitable study participation . Subject serious cardiovascular disease , include current New York Heart Association class II , class III IV congestive heart failure clinically significant valvular disease , history cardiac arrest , uncontrolled angina arrhythmia , chronic atrial fibrillation regardless ventricular rate , persistent atrioventricular conduction block &gt; first degree , acute myocardial ischemic condition suspect Electrocardiogram ( ECG ) screening ( e.g. , STsegment elevation , downsloping STsegment depression &gt; 2 mm ) . Subject myocardial infarction acute coronary syndrome , major heart surgery ( i.e. , valve replacement bypass surgery ) , stroke , deep vein thrombosis , pulmonary embolus past 6 month prior screen . Subject following , without blood pressure medication : pulse &lt; 40 &gt; 100 bpm ; mean systolic blood pressure &gt; 160 mmHg ; mean diastolic blood pressure &gt; 100 mmHg ( base measurement take triplicate subject rest supine position 5 minute ; pulse measure automatically ) day 1 . These assessment may repeat investigator 's discretion ( within screen window ) . Subject use follow drug : Strong cytochrome P450 ( CYP ) 3A4 inhibitor ( e.g. , itraconazole , clarithromycin ; within 14 day prior day 1 CYP3A4 inducer ( e.g. , barbiturate , rifampin ) within 14 day prior day 1 . Any medication know affect physical function muscle mass include androgen supplement , antiandrogens ( luteinizing hormonereleasing hormone [ LHRH ] agonist , antiestrogen [ tamoxifen , etc ] , . ) , recombinant human growth hormone [ rhGH ] insulin , oral beta adrenergic agonist , megestrol acetate , dronabinol , metformin drug ) might influence physical function muscle mass within 6 week prior screen . Subject significant blood loss , donate 1 unit ( 450 mL ) blood , receive transfusion blood blood product within 60 day donate plasma within 7 day prior screen . Subject has/had hemoglobin concentration 10.0 g/dL screening . Subject has/had &gt; 20 % weight loss previous 3 month prior screen . Subject has/had chronic medication introduce within 2 week prior screen . Subject has/had cancer require treatment currently past 3 year ( except primary nonmelanoma skin cancer , carcinoma situ cancer excellent prognosis early stage breast prostate cancer ) . Subject has/had diagnosed neurological condition neuromuscular disease cause impaired muscle function mobility . Subject current diagnosis schizophrenia , psychotic disorder bipolar disorder . Subject severe and/or uncontrolled medical condition could interfere study ( e.g. , severe neurological deficit stroke , diabetic peripheral neuropathy , respiratory disease require daytime supplemental oxygen , infection , gastrointestinal disorder , uncontrolled pain osteoarthritis would limit completion study procedure nonstable illness ) . Subject positive serology test hepatitis B surface antigen , hepatitis B core antibody , hepatitis A virus antibody ( immunoglobulin M ) , hepatitis C virus antibody , antibody human immunodeficiency virus ( HIV ) type 1 screening . Subject has/had surgical procedure require general anesthesia within 2 month prior screen , plan surgical procedure require general anesthesia study period . Subject use nonmedical compound , dietary aids/food supplement stable dose least 4 week prior screen and/or anticipate change dose regimen study . Subject history drug/chemical substance alcohol abuse within 2 year prior screen . Subject receive investigational therapy within 28 day 5 halflives , whichever longer , prior screen . Subject employee Astellas Group , Cytokinetics vendor involve study .</criteria>
	<gender>All</gender>
	<minimum_age>70 Years</minimum_age>
	<maximum_age>89 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>CK-2127107</keyword>
	<keyword>Mobility Limitation</keyword>
	<keyword>Phase 1b</keyword>
	<keyword>skeletal muscle fatigue</keyword>
</DOC>